Pyrazolone compounds and compositions and uses thereof

By developing pyrazolone compounds that specifically inhibit AXL kinase, the problem of AXL kinase activity inhibition in existing technologies has been solved, enabling effective treatment and prevention of various diseases, and exhibiting excellent inhibitory activity and pharmacokinetic properties.

CN115850301BActive Publication Date: 2024-11-15ZHONGSHAN INNOVATION BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211162439.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-09-24
Filing Date
2022-09-23
Publication Date
2024-11-15
Estimated Expiration
2042-09-23

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit the activity of AXL kinase, leading to treatment challenges for cancer drug resistance and viral infectious diseases, and there is a lack of inhibitors with good selectivity and pharmacokinetic properties.

Method used

A novel class of pyrazolone compounds has been developed that regulate the activity of AXL kinase by specifically inhibiting it, and can be used to treat proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, and viral infections.

Benefits of technology

This compound exhibits excellent inhibitory activity and kinase selectivity, possesses favorable pharmacokinetic properties, can enhance chemosensitivity, delay drug resistance, and is suitable for the treatment and prevention of various diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115850301B_ABST
    Figure CN115850301B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of medicine, and specifically relates to a pyrazolone compound represented by formula (I), or its stereoisomer, tautomer, nitrogen oxide, solvate, or pharmaceutically acceptable salt, and a pharmaceutical composition comprising the compound, and the use of the compound and the pharmaceutical composition in preparing a drug for treating and / or preventing proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, viral infectious diseases or other diseases in mammals. The compound provided by the present invention shows excellent inhibitory activity and kinase selectivity against target kinases. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention belongs to the field of medicine, and specifically relates to a new class of pyrazolone compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds, and the use of the compounds and pharmaceutical compositions thereof in the preparation of drugs for treating proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, viral infectious diseases or other diseases in mammals. More specifically, the compounds of the present invention can regulate the activity of AXL kinase, thereby regulating signal transduction inside and outside cells. Background of the Invention

[0002] The protein kinase family comprises a large class of structurally related enzymes that control various signal transduction processes within cells and catalyze the phosphorylation of target protein substrates. Many diseases are associated with abnormal cellular responses triggered by events mediated by protein kinases. These diseases include benign and malignant proliferative diseases, diseases caused by inappropriate activation of the immune system, allogeneic transplant rejection, graft-versus-host disease, autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease, and hormone-related diseases. Accordingly, the pharmaceutical field has developed effective protein kinase inhibitors for the treatment of the diseases.

[0003] Kinases can be divided into multiple families by phosphorylated substrates (e.g., protein-tyrosine, protein-serine / threonine, lipids, etc.). Tyrosine phosphorylation is one of the central events regulating various biological processes such as cell proliferation, migration, differentiation and survival. Receptor and non-receptor tyrosine kinases of multiple families control the transfer of catalytic phosphate from ATP to the tyrosine group of specific cellular protein targets. At present, the generally corresponding motifs of the above-mentioned various kinase families have been confirmed (Hanks et al., FASEB J., 1995, 9, 576-596; Knighton et al., Science, 1991, 253, 407-414; Garcia-Bustos en al. EMBO J., 1994, 13: 2352-2361). Examples of kinases in the protein kinase family include, but are not limited to, Aurora, Axl, abl, Akt, bcr-abl, Blk, Brk, Btk, c-Met, c-src, c-fms, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSF1R, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, F lt-3, Fak, fes, FGFRl, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, Fyn, AXL, IGF-1R, INS-R, KDR, Lck, Lyn, MEK, Me r, p38, PDGFR, PIK, PKC, PYK2, ros, Tie, Tie-2, TRK, Yes, Tyro3 and Zap70, etc. (Robinson, DR; Wu, YM; Lin, SFThe protein tyrosine kinase family of the human genome. Oncogene 2000,19,5548-5557).

[0004] Cancer (and other hyperproliferative diseases) are characterized by uncontrolled cell proliferation. The activity of many protein kinases is elevated in human tumors compared to normal tissues, and this elevated activity may be due to a number of factors, including elevated kinase levels, mutations in the expression of co-activators or inhibitory proteins.

[0005] AXL is a membrane-bound receptor tyrosine kinase, belonging to the TAM (Tyro3, ​​AXL, Mer) family. It is characterized by their two immunoglobulin-like domains and double fibronectin repeats in their extracellular domains and the kinase domain of related tyrosine in their cytoplasmic domains. (Linger, RMet al., TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Advances in cancer research 2008, 100, 35-83.). TAM receptor tyrosine kinase-mediated cell signaling participates in cell growth, migration, aggregation and apoptosis in a variety of normal cells. The TAM family has two known ligands GAS6 (growth arrest specificity 6) and protein S. Gas6 binding to AXL can lead to receptor dimerization and AXL autophosphorylation. (Stitt, TNet al., The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3 / Axl family of receptor tyrosinekinases. Cell 1995, 80(4), 661-70.) AXL is present in a variety of organs and cells, including epithelial cell lines, mesenchymal and hematopoietic origins, and untransformed cells.

[0006] AXL kinase is overexpressed or activated in many cancers, including ovarian cancer, melanoma, renal cell carcinoma, uterine leiomyoma, endometrial cancer, thyroid cancer, gastric cancer, breast cancer, NSCLC, CML, AML, colon cancer, prostate cancer, various lymphomas, and esophageal cancer. Recent studies have shown that AXL overexpression is particularly serious in cancer cells that develop resistance after chemotherapy and receptor tyrosine kinase inhibitor (TKI) treatment, and is one of the important reasons for drug resistance (Zhang, Z.; Lee, JC; Lin, L.; et al Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44, 852-860). At present, the emergence of drug resistance in cancer patients is still a difficult problem in the process of cancer treatment, and inhibiting AXL activity can enhance chemotherapy sensitivity and delay the occurrence of drug resistance. Therefore, AXL proto-oncogene is a very attractive and valuable target for discovering and developing new therapeutic agents (Feneyrolles C, Spenlinhauer A, Guiet L, et al. Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors. Mol Cancer Ther, 2014, 13 (9): 2141-2148). Based on the involvement in a variety of human malignancies, it is necessary to design specific and selective inhibitors to treat cancer and other diseases or conditions mediated by and / or related to AXL kinase. The present invention meets these needs and provides other related benefits.

[0007] Immunotherapy refers to a treatment method that artificially enhances or suppresses the body's immune function to achieve the purpose of treating diseases in response to the body's low or hyperactive immune state. There are many methods of immunotherapy, and they are applicable to the treatment of a variety of diseases. Tumor immunotherapy aims to activate the human immune system and rely on its own immune function to kill cancer cells and tumor tissues (Myers et al. Molecular Cancer, 2019, 18:94). Unlike previous surgery, chemotherapy, radiotherapy and targeted therapy, immunotherapy targets not tumor cells and tissues, but the body's own immune system.

[0008] Protein kinase inhibitors have attracted much attention as new immunomodulators, anti-inflammatory agents, and anticancer drugs. Therefore, new or improved agents that inhibit protein kinases such as AXL kinases can be used as immunomodulators, anti-tumor agents, analgesics, and anti-organ fibrosis drugs for organ transplantation. New or improved agents that inhibit AXL kinases can also be used to prevent and / or treat autoimmune diseases (e.g., multiple sclerosis, psoriasis, rheumatoid arthritis, asthma, type I diabetes, inflammatory bowel disease, Crohn's disease, polycythemia vera, essential thrombocythemia, myelofibrosis, autoimmune thyroid disease, Alzheimer's disease), diseases involving overactivated inflammatory responses (e.g., eczema), allergies, chronic obstructive pulmonary disease, bronchitis, and other diseases. Inflammation, fibrosis, cancer (e.g., gastric cancer, liver cancer, lung cancer, colorectal cancer, prostate cancer, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, leukemia, multiple myeloma) and other treatment-induced immune responses (e.g., rash, contact dermatitis or diarrhea), chronic pain and acute pain, or wherein the pain is associated with cancer, surgery, fracture, bone pain caused by tumor metastasis, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, interstitial cystitis, chronic pancreatitis, visceral pain, migraine, chronic low back pain, bladder pain syndrome or neuropathic pain, etc.

[0009] The TAM receptor tyrosine kinases Tyro3, ​​Axl, and Mer and their cognate ligands Protein S and Gas6 promote phagocytic clearance of apoptotic cells in the immune, nervous, and reproductive systems. They simultaneously drive a critical negative feedback loop that downregulates the host innate immune response mediated by the Toll-like receptor (TLR) and type I interferon signaling pathways. TAM receptor-ligand interactions have also been implicated in promoting cellular entry of enveloped viruses: ectopic introduction of one or more TAM receptors into infection-resistant cell lines has been found to enhance infection by filoviruses and lentiviruses. In addition to binding to TAM receptors via their carboxyl-terminal domains, the TAM ligands Protein S and Gas6 both contain glutamate-rich Gla domains at their amino termini that bind to phosphatidylserine (PtdSer) exposed on the surface of apoptotic cells and membrane-enclosed viral particles. (G. Lemke, CVRothlin, Nat Rev Immunol 8, 327 (May, 2008); G. Lemke, T. Burstyn-Cohen, Ann N YAcad Sci 1209, 23 (Oct, 2010).)

[0010] Enveloped viruses contain high levels of PtdSer on their surface and bind to the TAM ligand proteins S and Gas6 through PtdSer-Gla domain interactions. The function of TAM receptor-ligand interactions during enveloped virus infection is thought to be limited to promoting viral binding to target cells, thereby promoting viral infection. Membrane-bound TAM ligands are significantly more effective than free ligands in activating TAM receptor signaling, indicating that TAM ligands bind to PtdSer through their gla domains, altering the effects of the ligand on TAM signaling. AXL kinase inhibitors can block the interaction between AXL ligands and phosphatidylserine (PtdSer) in the membrane. Therefore, new or improved agents that inhibit protein kinases such as AXL kinase can be used as drugs for treating and / or preventing viral infectious diseases, for example, as drugs against Zika virus (iScience, 2019, 13, 339–350), coronavirus, new coronavirus (such as covid-19, etc.) and hepatitis B virus (HBV) (Journal of Hepatology 2015vol.63j670–678).

[0011] The compounds, compositions and methods described in the present invention directly correspond to the above needs and other purposes. Specifically, the present invention provides a class of compounds that inhibit, regulate and / or modulate the activity of AXL kinases for the treatment and / or prevention of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, pain, fibrosis, transplant rejection, or viral infectious diseases or their complications. Compared with existing similar compounds, the compounds of the present invention have better pharmacological activity. Specifically, the compounds of the present invention show excellent inhibitory activity and kinase selectivity for target kinases. In addition, the compounds of the present invention also have good pharmacokinetic properties. Therefore, the compounds of the present invention have very good development prospects. Summary of the invention

[0012] Definition of terms

[0013] Certain embodiments of the present invention are now described in detail, and examples thereof are illustrated by the accompanying structural formula and chemical formula. The present invention is intended to cover all substitutions, modifications and equivalent technical solutions, which are all included in the scope of the invention defined by the appended claims. It should be appreciated by those skilled in the art that many methods and materials similar or equivalent to those described in the present invention can be used to practice the present invention. The present invention is by no means limited to the methods and materials described in the present invention. In the case where one or more of the combined documents, patents and similar materials are different from or contradictory to the present application (including but not limited to defined terms, term applications, described technologies, etc.), the present application shall prevail.

[0014] "Stereoisomers" refer to compounds that have the same chemical constitution but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans) isomers, atropisomers, and the like.

[0015] As described herein, the compounds of the present invention may be optionally substituted with one or more substituents, such as the general compounds of the present invention, or as the specific examples, subclasses, and classes of compounds included in the embodiments.

[0016] It should be understood that the term "optionally substituted" can be used interchangeably with the term "substituted or unsubstituted". In general, the term "substituted" means that one or more hydrogen atoms in a given structure are replaced by a specified substituent. "Optionally" unless otherwise indicated, an optional substituent group can be substituted at each substitutable position of the group. When more than one position in a given structure can be substituted by one or more substituents selected from a specific group, the substituents can be substituted the same or differently at each position.

[0017] The term "optionally substituted by..." can be used interchangeably with the term "unsubstituted or substituted by...", i.e., the structure is unsubstituted or substituted by one or more substituents described in the present invention, and the substituents described in the present invention include, but are not limited to H, D, oxo (=O), F, Cl, Br, -OH, -CN, -NO2, -NR c R d 、-C(=O)R 9 、-OC(=O)R 9 、-C(=O)OR 9a 、-S(=O) 0-2 R 9 、-OS(=O) 1-2 R 9 、-S(=O) 1-2 OR 9a 、-OS(=O) 1-2 OR 9a 、-N(R 10a )C(=O)R 10 、-C(=O)NR 10a R 10 、-OC(=O)NR 10a R 10 、-N(R 10a )S(=O) 1-2 R 10 、-S(=O) 1-2 NR 10a R 10 、-N(R 10a)C(=O)NR 10a R 10 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6 Alkyl; wherein each C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy group substitution, etc. Among them, R c , R d , R 9 , R 9a , R 10 and R 10a Has the meaning as described in the present invention.

[0018] In various parts of this specification, the substituents of the disclosed compounds of the present invention are disclosed according to group types or ranges. It is particularly noted that the present invention includes each independent secondary combination of the individual members of these group types and ranges. For example, the term "C1-C6 alkyl" specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl.

[0019] The term "alkyl" or "alkyl group" as used herein refers to a saturated straight or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may be optionally substituted with one or more substituents described herein. Unless otherwise specified, the alkyl group contains 1-20 carbon atoms. In one embodiment, the alkyl group contains 1-12 carbon atoms; in another embodiment, the alkyl group contains 1-6 carbon atoms; in yet another embodiment, the alkyl group contains 1-4 carbon atoms; in yet another embodiment, the alkyl group contains 1-3 carbon atoms. The alkyl group may be optionally substituted with one or more substituents described herein.

[0020] Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -CH(CH3)CH2CH3), u, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl (-CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1 -butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3 ), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, and the like.

[0021] The term "alkenyl" refers to a straight or branched chain monovalent hydrocarbon radical containing 2 to 12 carbon atoms and having at least one site of unsaturation, i.e., a carbon-carbon sp 2 Double bonds, including "cis" and "trans" orientations, or "E" and "Z" orientations. In one embodiment, the alkenyl group contains 2-8 carbon atoms; in another embodiment, the alkenyl group contains 2-6 carbon atoms; in yet another embodiment, the alkenyl group contains 2-4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), and the like. The alkenyl group may be optionally substituted with one or more substituents described herein.

[0022] The term "alkynyl" refers to a straight or branched monovalent hydrocarbon group containing 2-12 carbon atoms, wherein there is at least one unsaturated site, i.e., one carbon-carbon sp triple bond. In one embodiment, the alkynyl group contains 2-8 carbon atoms; in another embodiment, the alkynyl group contains 2-6 carbon atoms; in yet another embodiment, the alkynyl group contains 2-4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propargyl (-CH2C≡CH), 1-propynyl (-C≡C-CH3), and the like. The alkynyl group may be optionally substituted with one or more substituents described herein.

[0023] The term "heteroalkyl" or "heteroalkyl group" used in the present invention refers to a monovalent alkyl group in which one or more carbon atoms are replaced by heteroatoms, and the alkyl group has the definition described in the present invention. Unless otherwise indicated, heteroalkyl includes but is not limited to a total of 1-20 atoms (i.e., carbon atoms and heteroatoms). The heteroalkyl group is optionally substituted as described for alkyl in the present invention. In some embodiments, heteroalkyl is unsubstituted. In some embodiments, the heteroatoms covered in the heteroalkyl group portion include O, N, S (i.e., including sulfoxide, sulfite, sulfate and sulfone), Si and P (i.e., including phosphite and phosphate), and / or combinations thereof. Non-limiting exemplary embodiments of heteroalkyl group portions include CH3O-, CH3OCH2-, CH3OCH2CH2-, CH3OCH2CH(CH3)-, CH3CH2OCH2CH(CH3)-, CH3CH2OCH2-, CH3CH2CH2OCH2-, etc.; -CH2NR a 、-CH2NR a CH2, -CH2NR a CH2CH2, -CH2CH2CH2NR a CH2, etc.; and CH3S-, CH3SCH2-, CH3SCH2CH2-, -CH2CH2CH2SCH3, etc., where R a Has the definition described in the present invention.

[0024] The term "alkoxy" means an alkyl group attached to the rest of the molecule via an oxygen atom, wherein the alkyl group has the definition as described herein. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In one embodiment, the alkoxy group contains 1-6 carbon atoms; in another embodiment, the alkoxy group contains 1-4 carbon atoms; in yet another embodiment, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may be optionally substituted with one or more substituents described herein.

[0025] Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-1-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentyloxy (n-pentyloxy, -OCH2CH2CH2CH2CH3), 2-pentyloxy (-OCH(CH3)CH2CH2CH3), 3-pentyloxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), and the like.

[0026] The term "haloalkyl" or "haloalkoxy" means that an alkyl or alkoxy group is substituted by one or more halogen atoms. Examples of such groups include, but are not limited to, trifluoromethyl (-CF3), trifluoromethoxy (-OCF3), difluoroethyl (-CH2CHF2, -CF2CH3, -CHFCH2F), trifluoroethyl (-CH2CF3, -CF2CH2F, -CFHCHF2), -CF(CH3)2, etc.

[0027] The terms "hydroxyalkyl" or "hydroxy-substituted alkyl" and "hydroxyalkoxy" or "hydroxy-substituted alkoxy" refer to an alkyl or alkoxy group, as the case may be, substituted with one or more hydroxy groups, wherein "hydroxyalkyl" and "hydroxyalkyl" are used interchangeably, such examples include, but are not limited to, hydroxymethyl (-CH2OH), 2-hydroxyethyl (-CH2CH2OH), 1-hydroxyethyl (-CH(OH)CH3), 2-hydroxypropan-2-yl (-COH(CH3)2), 2-hydroxy-2-methylpropyl (-CH2COH(CH3)2), 3-hydroxypropyl (-CH2CH2CH2OH), 2-hydroxypropyl (-CH2CH(OH)CH3), 2-hydroxy-2-methylpropyl (-CH2CH(OH)(CH3)CH3), hydroxymethoxy (-OCH2OH), 1,3-propanediol-2-yl (-CH(CH2OH)2), and the like.

[0028] The term "cyano-substituted alkyl" or "cyanoalkyl" includes C substituted with one or more cyano groups. 1-10 In some embodiments, the cyanoalkyl group is a C substituted with one or more cyano groups. 1-6 "Lower cyanoalkyl" is a C substituted with one or more cyano groups. 1-4 Examples of “lower cyanoalkyl” include, but are not limited to, CNCH2-, CNCH2CH2-, CNCH2CH2CH2-, CNCH2CHCNCH2-, and the like.

[0029] The term "alkylamino" includes "N-alkylamino" and "N,N-dialkylamino", wherein the amino groups are independently substituted with one or two alkyl groups. In some embodiments, the alkylamino group is one or two C 1-6 The alkyl group is a lower alkylamino group attached to the nitrogen atom. In some other embodiments, the alkylamino group is C 1-3 Suitable alkylamino groups may be monoalkylamino or dialkylamino, examples of which include, but are not limited to, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino, and the like.

[0030] The term "aminoalkyl" includes C 1-10 In some embodiments, aminoalkyl is a C substituted with one or more amino groups. 1-6 "Lower aminoalkyl" is another embodiment of aminoalkyl being a C substituted with one or more amino groups. 1-4 Examples of "lower aminoalkyl" include, but are not limited to, aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl.

[0031] The term "cycloalkyl" refers to a monovalent or multivalent saturated monocyclic, bicyclic or tricyclic ring system containing 3-12 carbon atoms. Bicyclic cycloalkyls include spirobicyclic alkyls, fused bicyclic alkyls and bridged bicyclic alkyls. In some embodiments, the cycloalkyl contains 3-12 carbon atoms; in other embodiments, the cycloalkyl contains 3-10 carbon atoms; in other embodiments, the cycloalkyl contains 3-8 carbon atoms; in other embodiments, the cycloalkyl contains 3-7 carbon atoms; in other embodiments, the cycloalkyl contains 3-6 carbon atoms; in still other embodiments, the cycloalkyl is C7-C 12 Cycloalkyl containing C7-C 12 Monocyclic alkyl, C7-C 12 Bicyclic alkyl (such as C7-C 12 Spirobicycloalkyl, C7-C 12Fused bicycloalkyl and C7-C 12 bridged bicycloalkyl) or C7-C 12 Tricycloalkyl. The cycloalkyl group can be independently unsubstituted or substituted by one or more substituents described in the present invention. The term "monocyclic cycloalkyl" or "monocyclic alkyl" represents a cycloalkyl of a monocyclic system, wherein the cycloalkyl has the definition as described above, and the monocyclic cycloalkyl group can be independently unsubstituted or substituted by one or more substituents described in the present invention. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl, 1-cyclohexyl-1-alkenyl, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, etc.

[0032] The term "cycloalkylalkyl" includes alkyl groups substituted with cycloalkyl. In some embodiments, the cycloalkylalkyl group refers to a "lower cycloalkylalkyl" group, i.e., a cycloalkyl group attached to a C 1-6 In other embodiments, a cycloalkylalkyl group refers to a C-containing 1-3 Specific examples include, but are not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopentylethyl, cyclohexylethyl, etc. The cycloalkyl on the cycloalkylalkyl group may be further substituted with one or more substituents described herein.

[0033] The terms "heterocyclyl" and "heterocycle" are used interchangeably herein and refer to a monocyclic, bicyclic or tricyclic ring system containing 3-12 ring atoms, monovalent or polyvalent, saturated or partially unsaturated, non-aromatic, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. In some embodiments, the heterocyclyl or heterocycle contains 4-12 ring atoms. In some embodiments, the heterocyclyl or heterocycle contains 5-12 ring atoms. In some embodiments, the heterocyclyl or heterocycle contains 4-8 ring atoms. In some embodiments, the heterocyclyl or heterocycle contains 3-8 ring atoms. In some embodiments, the heterocyclyl or heterocycle contains 3-6 ring atoms. In some embodiments, the heterocyclyl or heterocycle contains 4-7 ring atoms. Unless otherwise specified, the heterocyclyl group can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-, the sulfur atom of the ring can be optionally oxidized to S-oxide, and the nitrogen atom of the ring can be optionally oxidized to N-oxygen compound. Heterocyclic groups include saturated heterocyclic groups (heterocycloalkyl) and partially unsaturated heterocyclic groups. The heterocyclic group has one or more points of attachment to the rest of the molecule. Examples of heterocyclic groups include, but are not limited to: oxirane, azetidinyl, oxetanyl, thianilinyl, pyrrolidinyl, pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, 1,3-dioxolane, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, homopiperazinyl, homopiperidinyl, oxetanyl, thiol-cycloheptane, oxazepine Base (eg, 1,4-oxazepine 1,2-oxazepine , diazepine Base (eg, 1,4-diazepine 1,2-diazepine , dioxa Base (such as 1,4-dioxa 1,2-dioxa , thiazolin Base (such as 1,4-thiazepine 1,2-thiazepine 1,2,3,4-tetrahydroisoquinolinyl, 1,3-benzodioxolyl, 2-oxa-5-azabicyclo[2.2.1]hept-5-yl, 2-azaspiro[4.4]nonyl, 1,6-dioxaspiro[4.4]nonyl, 2-azaspiro[4.5]decyl, 8-azaspiro[4.5]decyl, 7-azaspiro[4.5]decyl, 3-azaspiro[5.5]undecyl, 2-azaspiro[5.5]undecyl, octahydro-1H-isoindolyl, octahydrocyclopenta[c]pyrrolyl, dihydroindolyl, 1,2,3,4-tetrahydroisoquinolinyl, hexahydrofuro[3,2-b]furanyl and dodecahydroisoquinolinyl, and the like. Examples of heterocyclic groups in which the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidone and 3,5-dioxopiperidinyl. Examples of heterocyclic groups in which the sulfur atom is oxidized include, but are not limited to, cyclopentane sulfone and 1,1-dioxothiomorpholinyl. The heterocyclic group may be optionally substituted by one or more substituents described herein.

[0034] In one embodiment, the heterocyclic group is a 4-7 atom heterocyclic group, which refers to a monovalent or polyvalent, saturated or partially unsaturated non-aromatic monocyclic or bicyclic ring containing 4-7 ring atoms, wherein at least one ring atom is selected from nitrogen, sulfur and oxygen atoms. Unless otherwise specified, the 4-7 atom heterocyclic group can be a carbon group or a nitrogen group, and the -CH2- group can be optionally replaced by -C(=O)-. The sulfur atom of the ring can be optionally oxidized to an S-oxide. The nitrogen atom of the ring can be optionally oxidized to an N-oxygen compound. The 4-7 atom heterocyclic group has one or more points of attachment to the rest of the molecule. Examples of monocyclic heterocyclic groups of 4 to 7 atoms include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopyranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl, dioxanyl, dithianyl, thioxanyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepanyl, 1,4-oxazepine 1,2-oxazepine , diazepine 1,4-diazepine Base, 1,2-diazepine yl) and thiazepine 1,4-thiazepine 1,2-thiazepine Examples of bicyclic heterocyclic groups composed of 4 to 7 atoms include, but are not limited to: 3-azabicyclo[3,2,0]heptane, 3-oxobicyclo[3,2,0]heptane, etc.; Examples of heterocyclic groups composed of 4 to 7 atoms in which -CH2- groups are replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolidinyl, oxo-1,3-thiazolidinyl, 2-piperidone and 3,5-dioxopiperidinyl; Examples of heterocyclic groups composed of 4 to 7 atoms in which sulfur atoms are oxidized include, but are not limited to, cyclopentanesulfonyl, 1,1-dioxotetrahydrothiophene, 1,1-dioxotetrahydrothiopyran, 1,1-dioxothiomorpholinyl. The heterocyclic groups composed of 4 to 7 atoms may be optionally substituted by one or more substituents described in the present invention.

[0035] The term "heterocyclylalkyl" includes alkyl groups substituted with heterocyclyl, wherein heterocyclyl and alkyl have the meanings described herein, such examples include, but are not limited to, tetrahydrofuranylmethyl, pyrrol-2-ylmethyl, morpholin-4-ylethyl, piperazin-4-ylethyl, piperidin-4-ylethyl, and the like.

[0036] The term "aryl" refers to monocyclic, bicyclic and tricyclic carbon ring systems containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, wherein at least one ring system is aromatic, wherein each ring system contains a ring consisting of 3-7 atoms and has one or more points of attachment to the rest of the molecule. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of aryl groups can include phenyl, naphthyl and anthracenyl. The aryl groups can be independently optionally substituted with one or more substituents described herein.

[0037] The term "arylalkyl" or "aralkyl" includes alkyl groups substituted with aryl. In some embodiments, the arylalkyl group refers to a "lower arylalkyl" group, i.e., an aryl group is attached to a C 1-6 In other embodiments, the arylalkyl group refers to a C 1-3 Specific examples include, but are not limited to, benzyl, diphenylmethyl, phenethyl, etc. The aryl group on the arylalkyl group may be further substituted with one or more substituents described in the present invention.

[0038] The term "heteroaryl" refers to monocyclic, bicyclic and tricyclic ring systems containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, wherein at least one ring is aromatic and at least one aromatic ring contains one or more heteroatoms, wherein each ring system contains 5-7 ring atoms and has one or more points of attachment to the rest of the molecule. The term "heteroaryl" can be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound". In one embodiment, heteroaryl is a heteroaryl containing 5-12 atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. In another embodiment, heteroaryl is a heteroaryl containing 5-10 atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. In another embodiment, heteroaryl is a heteroaryl containing 5-6 atoms containing 1, 2, 3 or 4 heteroatoms independently selected from O, S and N. The heteroaryl group is optionally substituted with one or more substituents described herein.

[0039] Examples of heteroaryl groups include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl , 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl; also includes the following bicyclic rings, but is by no means limited to these bicyclic rings: benzimidazolyl, benzofuranyl, benzothiophenyl, indolyl (such as 2-indolyl), purinyl, quinolyl (such as 2-quinolyl, 3-quinolyl, 4-quinolyl), isoquinolyl (such as 1-isoquinolyl), [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.

[0040] The term "heteroarylalkyl" means an alkyl group substituted by one or more heteroaryl groups, wherein the heteroaryl and alkyl groups have the meanings described herein, examples of which include, but are not limited to, pyridine-2-methyl, imidazole-2-methyl, furan-2-ethyl, indole-3-methyl, and the like.

[0041] The term "halogen" refers to F, Cl, Br or I.

[0042] The "pharmaceutically acceptable salt" used in the present invention refers to organic salts and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19. Pharmaceutically acceptable salts formed by non-toxic acids include, but are not limited to, inorganic acid salts formed by reaction with amino groups, such as hydrochlorides, hydrobromides, phosphates, sulfates, perchlorates, and organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, malonates, or other methods described in books and literature, such as ion exchange methods, to obtain these salts. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 The present invention also contemplates quaternary ammonium salts formed by any compound containing a N group. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C 1-8 Sulfonates and aromatic sulfonates.

[0043] The "solvate" of the present invention refers to an association formed by one or more solvent molecules and the compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid and aminoethanol. The term "hydrate" refers to an association formed by the solvent molecule being water.

[0044] Description of the compounds of the present invention

[0045] The present invention discloses a novel class of compounds that can be used as inhibitors of protein kinase activity, particularly AXL kinase activity. Compounds that are protein kinase inhibitors can be used to treat and / or prevent diseases, disorders, or conditions associated with inappropriate protein kinase activity, particularly inappropriate AXL kinase activity. Compared with existing similar compounds, the compounds of the present invention have better pharmacological activity, specifically, the compounds of the present invention show excellent inhibitory activity and kinase selectivity against target kinases. In addition, the compounds of the present invention also have good pharmacokinetic properties. Therefore, the compounds of the present invention have very good development prospects.

[0046] The compounds disclosed in the present invention can show strong inhibitory activity against one or more protein kinases. In one aspect, the present invention relates to a pyrazolone compound having a structure shown in formula (I):

[0047]

[0048] or a stereoisomer, tautomer, nitrogen oxide, solvate, or pharmaceutically acceptable salt thereof; wherein,

[0049] U1 and U2 are independently N or -C(R a )-;

[0050] R 1 and R 2 Each independently is H, D, C 2-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6Alkyl; wherein each C 2-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Hydroxyalkyl, C 2-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-12 Aryl, C 6-12 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted with 0, 1, 2, 3 or 4 R 11 replace;

[0051] R a , R 3 , R 4 , R 5 and R 8 , each occurrence is independently H, D, F, Cl, Br, -OH, -CN, -NO2, -NR c R d , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6 Alkyl; wherein each -NR c R d , C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 3-8 Cycloalkyl, C3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted with 0, 1, 2, 3 or 4 R 12 replace;

[0052] or R 2 and R 3 Together with the carbon atoms and nitrogen atoms to which they are attached, they optionally form a heterocyclic ring of 4 to 12 atoms, wherein the heterocyclic ring of 4 to 12 atoms optionally contains 1, 2 or 3 heteroatoms independently selected from N, O, and / or S and is optionally substituted by 0, 1, 2, 3, 4 or 5 R 13 replace;

[0053] R 6 and R 7 Each independently is H, D, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 1-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl, C 2-10 Heterocyclic group, C 2-10 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6 Alkyl; wherein each C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 1-10 Heteroalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl, C 2-10 Heterocyclic group, C 2-10 Heterocyclyl C 1-6 Alkyl, C 6-10Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted with 0, 1, 2, 3, 4, or 5 R 14 replace;

[0054] R 11 , R 12 , R 13 and R 14 , each occurrence is independently H, D, oxo (=O), F, Cl, Br, -OH, -CN, -NO2, -NR c R d 、-C(=O)R 9 、-OC(=O)R 9 、-C(=O)OR 9a 、-S(=O) 0-2 R 9 、-OS(=O) 1-2 R 9 、-S(=O) 1-2 OR 9a 、-OS(=O) 1-2 OR 9a 、-N(R 10a )C(=O)R 10 、-C(=O)NR 10a R 10 、-OC(=O)NR 10a R 10 、-N(R 10a )S(=O) 1-2 R 10 、-S(=O) 1-2 NR 10a R 10 、-N(R 10a )C(=O)NR 10a R 10 , C 1-6 Alkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6 Alkyl; wherein each -NR c R d 、-C(=O)R 9 、-OC(=O)R 9 、-C(=O)OR 9a 、-S(=O) 0-2 R 9 、-OS(=O) 1-2 R 9 、-S(=O) 1-2 OR 9a 、-OS(=O) 1-2 OR 9a 、-N(R 10a )C(=O)R 10 、-C(=O)NR 10a R 10 , C 1-6 Alkyl, C 1-6 Heteroalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 1-6 Aminoalkyl, C 1-6 Cyanoalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy group substitution;

[0055] R c , R d , R9 , R 9a , R 10 and R 10a , at each occurrence, are independently H, D, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-6 Alkyl; wherein each C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy group substitution; and

[0056] n is 0, 1, or 2.

[0057] In some embodiments, the compound has a structure shown in formula (II):

[0058]

[0059] or a stereoisomer, tautomer, N-oxide, solvate, or pharmaceutically acceptable salt thereof;

[0060] in,

[0061] X 1 O, S, -N(R 13a)-、-C(=O)-、-(CH2) t1 -、-X 2 -(CH2) t1 -, or -(CH2) t1 -X 2 -(CH2) t2 -;

[0062] X 2 O, S, -N(R 13a )-, or -C(=O)-;

[0063] Each R 13a H, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-12 Aryl, C 6-12 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl, C 1-9 Heteroaryl C 1-6 Alkyl, -C(=O)R 9 、-C(=O)OR 9a 、-S(=O) 0-2 R 9 、-S(=O) 1-2 OR 9a 、-S(=O) 1-2 NR 10a R 10 , or -C(=O)NR 10a R 10 , wherein each C 1-6 Alkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-6 Alkyl, C 2-7 Heterocyclic group, C 2-7 Heterocyclyl C 1-6 Alkyl, C 6-12 Aryl, C 6-12 Aryl C 1-6 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-6 The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl and C 1-6Alkoxy group substitution;

[0064] t1 and t2 are each independently 0, 1, 2, 3, or 4; and

[0065] m is 0, 1, 2, 4, or 5.

[0066] In some embodiments, wherein R 1 It is C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Hydroxyalkyl, C 2-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 3-8 cycloalkyl, phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrazolyl, or triazolyl; wherein each C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Hydroxyalkyl, C 2-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 3-8 Cycloalkyl, phenyl, pyridyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrazolyl and triazolyl are independently optionally substituted with 0, 1, 2, 3 or 4 R 11 replace.

[0067] In some embodiments, wherein

[0068] R 2 It is H, C 2-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Hydroxyalkyl, C 2-4 Aminoalkyl, or C 1-4 Cyanoalkyl; wherein each C 2-4 Alkyl, C 1-4 Haloalkyl, C 2-4 Hydroxyalkyl, C 2-4 Aminoalkyl and C 1-4 Cyanoalkyl is optionally substituted independently by 0, 1, 2, 3 or 4 R 11 replace;

[0069] R 3 It is H, D, F, -CN, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, or C 1-4 Cyanoalkyl; wherein each C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl and C1-4 Cyanoalkyl is optionally substituted independently by 0, 1, 2, 3 or 4 R 12 replace;

[0070] or R 2 and R 3 Together with the carbon atom and the nitrogen atom to which it is attached, it optionally forms a heterocyclic ring consisting of 4 to 7 atoms, wherein the heterocyclic ring consisting of 4 to 7 atoms optionally contains 1, 2 or 3 heteroatoms independently selected from N, O, and / or S and is optionally substituted by 0, 1, 2, 3, 4 or 5 R 13 replace.

[0071] In some embodiments, wherein R 6 and R 7 Each independently is H, D, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 1-6 Heteroalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-4 Alkyl; wherein each C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 1-6 Heteroalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-4 The alkyl group is optionally substituted with 0, 1, 2, 3, 4, or 5 R 14 replace.

[0072] In some embodiments, wherein

[0073] R 6 Is H or C 1-4 Alkyl; and

[0074] R 7 It is H, C 1-6 Alkyl, C 1-4 Heteroalkyl, C 1-4 Fluorinated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 Alkyl, C 3-6 Heterocyclyl C 1-3 Alkyl, phenyl-C 1-3 Alkyl-, or heteroaryl-C 1-3 alkyl-;

[0075] Among them, R 6 and R 7 Each C in 1-6 Alkyl, C 1-4 Heteroalkyl, C 1-4 Fluorinated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 Alkyl, C 3-6 Heterocyclyl C 1-3 Alkyl, phenyl-C 1-3 Alkyl- and 5-6 atoms composed of heteroaryl-C 1-3 Alkyl - optionally substituted independently by 0, 1, 2, 3, 4, or 5 R 14 replace.

[0076] In some embodiments, wherein

[0077] R 6 is H, methyl, or ethyl; and

[0078] R 7 is H, methyl, ethyl,

[0079] In some embodiments, wherein R a , R 4 , R 5 and R 8 , each time it occurs, is independently H, D, F, Cl, Br, -OH, -CN, -NO2, -NH2, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-4 Alkyl; wherein each C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-4 The alkyl group is optionally substituted with 0, 1, 2, 3 or 4 R 12 replace.

[0080] In some embodiments, wherein R 11 , R 12 , R 13 and R 14 , each occurrence is independently H, D, oxo (=O), F, Cl, Br, -OH, -CN, -NO2, -NR c R d 、-C(=O)R 9 、-OC(=O)R 9 、-C(=O)OR 9a 、-S(=O) 0-2 R 9 、-OS(=O) 1-2 R 9 、-S(=O) 1-2 OR 9a 、-OS(=O) 1-2 OR 9a 、-N(R 10a )C(=O)R10 、-C(=O)NR 10a R 10 、-OC(=O)NR 10a R 10 、-N(R 10a )S(=O) 1-2 R 10 、-S(=O) 1-2 NR 10a R 10 、-N(R 10a )C(=O)NR 10a R 10 , C 1-4 Alkyl, C 1-4 Heteroalkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 1-4 Alkoxy, C 1-4 Alkylamino, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-4 Alkyl; wherein each -NR c R d 、-C(=O)R 9 、-C(=O)OR 9a 、-OS(=O) 1-2 R 9 、-S(=O) 1-2 OR 9a 、-OS(=O) 1-2 OR 9a , C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 1-4 Aminoalkyl, C 1-4 Cyanoalkyl, C 1-4 Alkoxy, C 1-4 Alkylamino, C 3-6 Cycloalkyl, C3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-4 The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-4 Alkyl and C 1-4 Alkoxy groups are substituted.

[0081] In some embodiments, wherein R c , R d , R 9 , R 9a , R 10 and R 10a , at each occurrence, are independently H, D, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl, or C 1-9 Heteroaryl C 1-4 Alkyl; wherein each C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-4 Alkyl, C 3-6 Heterocyclic group, C 3-6 Heterocyclyl C 1-4 Alkyl, C 6-10 Aryl, C 6-10 Aryl C 1-4 Alkyl, C 1-9 Heteroaryl and C 1-9 Heteroaryl C 1-4The alkyl group is optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, oxo (=O), F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-4 Alkyl and C 1-4 Alkoxy groups are substituted.

[0082] In some embodiments, the compound is a compound having one of the following structures:

[0083]

[0084]

[0085]

[0086] or a stereoisomer, tautomer, nitrogen oxide, solvate, or pharmaceutically acceptable salt thereof.

[0087] Unless otherwise indicated, stereoisomers, tautomers, solvates, metabolites or pharmaceutically acceptable salts of the compounds represented by formula (I) or (II) are all within the scope of the present invention.

[0088] The compounds disclosed in the present invention may contain asymmetric or chiral centers and therefore may exist in different stereoisomeric forms. The present invention is intended to make all stereoisomeric forms of the compounds represented by formula (I) or (II), including but not limited to diastereomers, enantiomers, atropisomers and geometric (or conformational) isomers, and mixtures thereof such as racemic mixtures, become part of the present invention.

[0089] In structures disclosed herein, when the stereochemistry of any particular chiral atom is not indicated, all stereoisomers of the structure are contemplated within the present invention and are included as compounds disclosed herein. When stereochemistry is indicated by a solid wedge or dashed line representing a particular configuration, the stereoisomers of the structure are thus unambiguous and defined.

[0090] The compound shown in formula (I) or (II) may exist in the form of a salt. In one embodiment, the salt refers to a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammal treated therewith. In another embodiment, the salt is not necessarily a pharmaceutically acceptable salt, and may be an intermediate for preparing and / or purifying the compound shown in formula (I) or (II) and / or for separating the enantiomer of the compound shown in this formula (I) or (II).

[0091] In another aspect, the present invention relates to an intermediate for preparing a compound represented by formula (I) or (II).

[0092] In another aspect, the present invention relates to methods for preparing, separating and purifying the compounds represented by formula (I) or (II).

[0093] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the present invention. In one embodiment, the pharmaceutical composition of the present invention further comprises a pharmaceutically acceptable excipient, diluent or carrier, or a combination thereof. In another embodiment, the pharmaceutical composition can be a liquid, solid, semi-solid, gel or spray formulation.

[0094] In some embodiments, the pharmaceutical composition described herein further comprises an additional therapeutic agent.

[0095] In another aspect, the present invention relates to use of the compound or pharmaceutical composition of the present invention in preparing a medicament for preventing and / or treating diseases and / or conditions mediated by AXL protein kinase.

[0096] In some embodiments, the disease and / or disorder is selected from a proliferative disease, an autoimmune disease, an allergic disease, an inflammatory disease, transplant rejection, or a viral infectious disease.

[0097] In some embodiments, the disease and / or condition is selected from the group consisting of treating and / or preventing AXL kinase-mediated diseases involving signaling pathways. Such diseases and / or conditions include proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, and complications thereof. In particular, the compounds of the present invention can be used to treat and / or prevent the following diseases and / or conditions, including, but not limited to, cancer (including solid tumors and blood cancers), polycythemia vera, essential thrombocythemia, myelofibrosis, myelocytic leukemia, acute lymphocytic leukemia, chronic myeloid leukemia (CML), chronic obstructive pulmonary disease (COPD), asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type I diabetes, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, influenza, coronavirus infection, novel coronavirus infection, dengue virus infection, Zika virus infection, Ebola virus infection, respiratory syncytial virus infection, or HBV.

[0098] Pharmaceutical compositions, preparations and administration of the compounds of the present invention

[0099] The present invention provides a pharmaceutical composition, which comprises a compound disclosed in the present invention, or a compound listed in the embodiments, or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite or pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient, diluent, carrier, solvent or a combination thereof. The amount of the compound in the pharmaceutical composition disclosed in the present invention refers to an amount that can effectively detect the inhibition of protein kinase in a biological sample or a patient.

[0100] It should also be recognized that certain compounds of the present invention may be used in free form for treatment, or, if appropriate, in the form of pharmaceutically acceptable derivatives thereof. Some non-limiting embodiments of pharmaceutically acceptable derivatives include pharmaceutically acceptable salts, esters, salts of these esters, or any other adducts or derivatives that can directly or indirectly provide the compounds of the present invention or their metabolites or residues when administered to a patient in need thereof.

[0101] In document such as Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. DB Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and JC Boylan, 1988-1999, Marcel Dekker, New York, various carriers for configuring pharmaceutically acceptable compositions, and known techniques for their preparation are disclosed, and the respective contents of these documents are incorporated by reference into the present invention. Except any commonly used carriers such as those which are incompatible with the disclosed compounds of the present invention due to any undesirable biological effects or any other components in the pharmaceutically acceptable compositions interacting in a harmful manner, it is concerned that their application belongs to the scope of the present invention.

[0102] The pharmaceutical composition provided by the present invention can be co-formulated with other active ingredients that do not impair the intended therapeutic effect, or co-formulated with substances that supplement the intended effect.

[0103] Uses of the compounds and compositions of the present invention

[0104] The present invention provides methods of using the compounds and pharmaceutical compositions disclosed herein to treat, prevent, or ameliorate diseases or conditions mediated or otherwise affected by the action of one or more protein kinases, such as AXL kinase, or one or more symptoms of a disease or condition mediated or otherwise affected by the action of AXL kinase.

[0105] In some embodiments, the present invention provides a class of compounds disclosed herein or pharmaceutical compositions comprising compounds disclosed herein for treating, preventing or ameliorating a disease or condition mediated or otherwise affected by inappropriate AXL kinase activity or one or more symptoms of a disease or condition mediated or otherwise affected by inappropriate AXL kinase activity.

[0106] "Inappropriate AXL kinase behavior" refers to AXL kinase behavior that deviates from normal AXL kinase behavior in a particular patient. Inappropriate AXL kinase behavior can take the form of, for example, an abnormal increase in activity, or deviations in the timing and control of AXL kinase behavior. Such inappropriate kinase behavior results from, for example, overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled behavior. Thus, the present invention provides methods for treating these diseases and conditions.

[0107] Consistent with the above description, such diseases or disorders include, but are not limited to: myeloproliferative diseases, such as polycythemia vera (PCV), essential thrombocythemia, idiopathic myelofibrosis (IMF); leukemia, such as myeloid leukemia including chronic myeloid leukemia (CML), imatinib-resistant CML forms, acute myeloid leukemia (AML) and subtypes of AML, acute megakaryoblastic leukemia (AMKL); lymphoproliferative diseases, such as acute lymphoblastic leukemia (ALL) and myeloma, etc.; cancers including head and neck cancer, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancer, brain tumors, Pancreatic cancer, urothelial cancer, liver cancer, gastric cancer and kidney cancer, etc.; and inflammatory diseases or conditions related to immune dysfunction, immunodeficiency, immune regulation, autoimmune diseases, tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, psoriasis, allergic rhinitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis (UC), systemic lupus erythematosus (SLE), arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma and chronic obstructive pulmonary disease (COPD) and dry eye syndrome (or keratoconjunctivitis sicca (KCS)).

[0108] In one aspect, the present invention provides a class of compounds disclosed herein or pharmaceutical compositions comprising compounds disclosed herein for use in preventing and / or treating proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, or transplant rejection in mammals (including humans).

[0109] In another aspect, the present invention provides a method of treating a mammal suffering from or at risk of suffering from a disease disclosed herein, the method comprising administering an effective amount of treating the disease or an effective amount of preventing the disease to one or more pharmaceutical compositions or compounds disclosed herein.

[0110] In a specific embodiment, the proliferative disease is selected from cancer, such as colon cancer, malignant glioma, endometrial cancer, liver cancer, lung cancer, melanoma, kidney cancer, thyroid cancer, lymphoma, lymphoproliferative disorder, small cell lung cancer, squamous cell lung cancer, glioma, breast cancer, prostate cancer, ovarian cancer, cervical cancer, etc.; hematological malignancies, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative disease (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukemia (T-ALL), B-cell acute lymphoblastic leukemia (B-ALL), non-Hodgkin's lymphoma (NHL), B-cell lymphoma; polycythemia vera, essential thrombocythemia, myelofibrosis, multiple myeloma, etc.

[0111] In another aspect, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from an autoimmune disease, the method comprising administering a therapeutically effective amount or a prophylactically effective amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0112] In certain embodiments, the autoimmune disease is selected from the group consisting of COPD, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type I diabetes, and inflammatory bowel disease.

[0113] In another aspect, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from an allergic disease, the method comprising administering an effective therapeutic amount or an effective preventive amount of one or more pharmaceutical compositions or compounds disclosed herein. In a specific embodiment, the allergic disease is selected from respiratory allergic diseases, sinusitis, eczema and measles, food allergies and insect venom allergies.

[0114] In a particular embodiment, the allergic disease is selected from the group consisting of respiratory allergic disease, sinusitis, eczema and hives, food allergies and allergies to insect venoms.

[0115] In another aspect, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from an inflammatory disease, the method comprising administering a therapeutically effective amount or a prophylactically effective amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0116] In another aspect, the present invention provides a method for treating and / or preventing a mammal susceptible to or suffering from a viral infectious disease, the method comprising administering an effective therapeutic amount or an effective preventive amount of one or more pharmaceutical compositions or compounds disclosed herein.

[0117] In certain embodiments, the viral infectious disease is selected from influenza, coronavirus infection, novel coronavirus infection, dengue virus infection, Zika virus infection, Ebola virus infection, respiratory syncytial virus infection, or HBV.

[0118] In another aspect, the present invention provides a class of compounds disclosed herein for use as a medicament, particularly as a medicament for treating and / or preventing the diseases and / or conditions described herein. The present invention also provides a medicament for treating and / or preventing the diseases and / or conditions described herein using the compounds disclosed herein.

[0119] Combination therapy

[0120] The compounds of the invention may be administered as the sole active agent, or may be administered in combination with other therapeutic agents, including other compounds that have the same or similar therapeutic activity and that are determined to be safe and effective for such combination administration.

[0121] In one aspect, the present invention provides a method for treating, preventing or ameliorating a disease or condition, comprising administering a safe and effective amount of a combination drug comprising a compound disclosed herein and one or more therapeutically active agents. In some embodiments, the combination drug comprises one or two other therapeutic agents.

[0122] Examples of other therapeutic agents include, but are not limited to: anti-cancer agents, including chemotherapeutic agents and anti-proliferative agents; anti-inflammatory agents; and immunomodulatory or immunosuppressive agents.

[0123] On the other hand, the present invention provides products including compounds of the present invention and at least one other therapeutic agent, which can be prepared as a combination for simultaneous, separate or sequential administration in treatment. In some embodiments, the treatment is for the treatment of diseases or symptoms mediated by one or more protein kinases, such as AXL kinase, or NTRK kinase activity. The products provided by the combined preparation include compositions present in the same pharmaceutical composition and containing compounds disclosed herein and other therapeutic agents, or compounds disclosed herein and other therapeutic agents in different forms, for example, a kit.

[0124] In another aspect, the present invention provides a pharmaceutical composition comprising a compound disclosed herein and one or more additional therapeutic agents. In some embodiments, the pharmaceutical composition may comprise a pharmaceutically acceptable excipient as described above.

[0125] On the other hand, the present invention provides a medicine box comprising two or more separate pharmaceutical compositions, wherein at least one pharmaceutical composition comprises a disclosed compound of the present invention. In some embodiments, the medicine box includes a tool for separately holding the composition, such as a container, a separate bottle or a separate foil box. An example of such a medicine box is a blister package, which is commonly used for packaging tablets, capsules, etc.

[0126] The compounds disclosed herein can be administered as the sole active ingredient or co-administered with other therapeutic agents, for example, as an adjuvant.

[0127] In some embodiments, the other therapeutic agent includes a chemotherapeutic agent and / or an antiproliferative agent. Known chemotherapeutic agents include, but are not limited to, other therapeutics or anticancer drugs that can be used in combination with the compounds of the present invention, surgery, radiation therapy (a few examples are gamma radiation, neutron beam radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy and systemic radioisotope therapy), endocrine therapy, taxanes (taxol, docetaxel, etc.), platinum derivatives (cisplatin, carboplatin), biological response modifiers (interferon, interleukin), tumor necrosis factor (TNF, TRAIL receptor target), hyperthermia. and cryotherapy, agents to mitigate any adverse effects (e.g., antiemetics), and other approved chemotherapeutic agents, including, but not limited to, alkylating agents (mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide), antimetabolites (methotrexate, pemetrexed, etc.), purine antagonists and pyrimidine antagonists (6-mercaptopurine), opurine, 5-fluorouracil, cytarabile, gemcitabine), spindle inhibitors (vinblastine, vincristine, vinorelbine), podophyllotoxins (etoposide, irinotecan, topotecan), antibiotics (doxorubicin, bleomycin), cin), mitomycin), nitrosoureas (carmustine, lomustine), cell cycle inhibitors (KSP through mitotic kinesin inhibitors, CENP-E and CDK inhibitors), enzymes (asparaginase), hormones (tamoxifen, leuprolide, flutamide, megestrol, dexamethasone, etc.). Anti-angiogenic agents (avastin, etc.).Monoclonal antibodies (belimumab, brentuximab, cetuximab, gemtuzumab, ipilimumab, ofatumumab, panitumumab, ranibizumab, rituximab, tositumomab, trastuzumab). Kinase inhibitors (imatinib, sunitinib, sorafenib, erlotinib, gefitinib, dasatinib, nilotinib, lapatinib, crizotinib, ruxolitinib, vemurafenib, vandetanib, pazopanib, etc.) Drugs that inhibit or activate cancer pathways such as mTOR, HIF (hypoxia inducible factor) pathways, and others.

[0128] The compounds disclosed in the present invention can also be combined with other treatment processes to improve the efficacy. For example, hormone therapy or special radiotherapy is administered. The compounds disclosed in the present invention are particularly used as radiosensitizers, especially for the treatment of tumors that are weakly sensitive to radiotherapy.

[0129] "Combination" means a fixed combination in a single dosage unit form or a kit of parts for combined administration, wherein the compounds disclosed herein and the combination partner can be administered independently at the same time or can be administered separately within a certain time interval, especially so that the combination partner exhibits a cooperative, such as synergistic effect. As used herein, the term "co-administration" or "combined administration" and the like are intended to encompass administration of the selected combination partner to a single individual (e.g., patient) in need thereof, and are intended to include treatment regimens in which the substances are not necessarily administered by the same route of administration or at the same time.

[0130] Treatment

[0131] In some embodiments, the treatment methods disclosed herein include administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention to a patient in need thereof. The various embodiments disclosed herein include methods for treating the diseases or conditions described herein by administering a safe and effective amount of a compound of the present invention or a pharmaceutical composition comprising a compound of the present invention to a patient in need thereof.

[0132] In some embodiments, the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention can be administered once, or according to the dosing regimen, several times at different time intervals within a specified time period. For example, once, twice, three times or four times a day. In one embodiment, it is administered once a day. In another embodiment, it is administered twice a day. It can be administered until the desired therapeutic effect is achieved or the desired therapeutic effect is maintained indefinitely. The suitable dosing regimen of the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention depends on the pharmacokinetic properties of the compounds, such as dilution, distribution and half-life, which can be determined by technicians. In addition, the suitable dosing regimen of the compounds disclosed in the present invention or the pharmaceutical composition comprising the compounds disclosed in the present invention, including the duration of the implementation of the regimen, depends on the disease being treated, the severity of the disease being treated, the age and physical condition of the patient being treated, the medical history of the patient being treated, the nature of the concurrent therapy, the desired therapeutic effect, and other factors within the knowledge and experience of the technician. The technical personnel in the field should also understand that the appropriate dosing regimen may be required to be adjusted for the response of individual patients to the dosing regimen, or when the needs of individual patients change over time.

[0133] The compounds disclosed in the present invention can be administered simultaneously with, before or after, one or more other therapeutic agents. The compounds disclosed in the present invention can be administered separately with other therapeutic agents through the same or different administration routes, or in the form of the same pharmaceutical composition.

[0134] General synthetic scheme

[0135] To describe the present invention, the following examples are listed. However, it should be understood that the present invention is not limited to these examples, which are only provided to provide methods for practicing the present invention.

[0136] Generally, the compounds of the present invention can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are defined as shown in formula (I) or (II). The following reaction schemes and examples are used to further illustrate the content of the present invention.

[0137] In the examples described below, all temperatures are set in degrees Celsius unless otherwise indicated. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Alfa Chemical Company, Shanghai Shaoyuan Reagent Co., Ltd., SAIN Chemical Technology (Shanghai) Co., Ltd., Shanghai Baide Pharmaceutical Technology Co., Ltd., and Shanghai Haohong Biomedical Technology Co., Ltd. Unless otherwise specified, the reagents used in the present invention can be used without further purification. Common solvents were purchased from commercial suppliers such as Beijing Haizhiyuan Weiye Technology Co., Ltd.

[0138] Anhydrous THF, dioxane, DCM, toluene and DMF were purchased from commercial suppliers, such as Energychemical Company and Aldrich Chemical Company. EtOAc, PE, CH3CN, NMP and DMSO were treated with anhydrous Na2SO4 before use.

[0139] The following reactions were generally carried out under positive pressure of nitrogen or argon or with a drying tube over anhydrous solvents (unless otherwise indicated), reaction bottles were plugged with appropriate rubber stoppers, and substrates were injected via syringes. All glassware was dried.

[0140] The chromatographic column used was a silica gel column, and the silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Plant.

[0141] 1 H NMR spectra and 13 The C / 2D data were collected on a Bruker Avance III 400 MHz. 1 H NMR spectra were obtained in CDC13, DMSO-d6, CD3OD or acetone-d6 as solvents (in ppm) and TMS (0 ppm) or chloroform (7.26 ppm) as reference standards. When multiple peaks are present, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), br (broadened), brs (broadened singlet), dd (doublet of doublets), dt (doublet of triplets). Coupling constants are expressed in Hertz (Hz).

[0142] LC / MS was performed on an Agilent 1260 (binary pump / DAD detector) coupled to an Agilent 6120 / 6125 mass spectrometer.

[0143] Method 1:

[0144] Column: HALO C18 2.7 μm, 4.6 mm×30 mm, mobile phase: MeCN (0.05% HCOOH)-Water (0.05% HCOOH); gradient: from 5% to 95% MeCN, elution 0.8 min, hold 0.8 min, total run time is 2.0 min; flow rate: 1.8 mL / min; column temperature: 45°C;

[0145] Method 2:

[0146] Column: HALO C18 2.7 μm, 4.6 mm×50 mm, mobile phase: MeCN (0.025% trifluoroacetic acid)-water (0.025% trifluoroacetic acid); gradient: from 5% to 95% MeCN, elution 1.0 min, hold 1.0 min, total run time is 2.5 min; flow rate: 1.8 mL / min; column temperature: 45°C.

[0147] Purity test by RP-HPLC:

[0148] Compound purity test on RP-HPLC (Shimadzu 2010 / 2030)

[0149] Method 1:

[0150] Column: Gemini 4.6×150 mm 5 um; Mobile phase: H2O (0.05% trifluoroacetic acid)-MeCN (0.05% trifluoroacetic acid). Gradient:

[0151] From 10% to 100% MeCN, elution for 8 minutes, hold for 2 minutes. Flow rate: 1.2 mL / min, column temperature: 35°C / 40°C.

[0152] Method 2:

[0153] Column: XBRIDGE 2.1×50 mm, 3.5 um; Mobile phase: H2O (0.05% trifluoroacetic acid)-MeCN (0.05% trifluoroacetic acid). Gradient: from 10% to 100% MeCN, elution for 7 minutes, hold for 1 minute. Flow rate: 0.8 mL / min, column temperature: 35°C / 40°C.

[0154] Compound purification by SFC:

[0155] SFC purification was performed on a Thar P80 equipped with UV detection.

[0156] Method: Column CHIRALPAK AD-H 250 mm, 20 mm, 5 μm, modifier: 30% EtOH (0.2% NH4OH).

[0157] Compound purification by RP-HPLC:

[0158] RP-HPLC purification was performed on a Gilson purification system (322 or 306 pump and GX-281 fraction collector), Shimadzu LC20Ap, and Waters MS triggered purification system;

[0159] Method 1:

[0160] Columns Gemini C18 21x150mm, 5μm Xbrige C18 19x150mm, 5μm, Spolar C18 20x150mm and Ultimate AQ-C18 30x250mm, 10μm

[0161] Mobile Phase:

[0162] 1. MeCN in water (0.1% HCOOH), flow rate: 20 ml / min, 50 ml / min, column 30x250 mm, 10 μm; wavelength: 210-400 nm. Inject the sample into DMSO (+optional formic acid and water), elute with a linear gradient from 10% to 95% MeCN over 10 minutes.

[0163] 2. MeCN in water (0.1% trifluoroacetic acid), flow rate: 20 ml / min, 50 ml / min, column 30x250 mm, 10 μm; wavelength: 210-400 nm. Samples were injected into DMSO (+optional formic acid and water), eluted with a linear gradient from 10% to 95% MeCN over 10 minutes.

[0164] 3. Aqueous solution of MeCN (0.1% NH3-H2O / 10mM NH4AC), flow rate: 20ml / min, 50ml / min, column 30x250 mm, 10μm; wavelength: 210-400nm. The sample was injected into DMSO (+optional formic acid and water), and eluted with a linear gradient from 10% to 95% MeCN for 10 minutes.

[0165] Typical synthetic steps for preparing the compounds disclosed in the present invention are shown in the following synthetic schemes. 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 、U1、U2、X 1 and n have the same meaning as described in the present invention; PG 1 It is a protecting group.

[0166] Synthesis Scheme 1:

[0167]

[0168] The compound of formula I of the present invention can be synthesized as shown in Scheme 1. Compound (i) and compound (ii) can undergo SN2 nucleophilic reaction or CO coupling standard reaction under alkaline conditions to obtain compound (iii), wherein Y1 represents halogen, preferably F or Cl. Under alkaline conditions, using elemental iodine or NY2S (NY2S = N-chlorosuccinamide, N-bromosuccinamide or N-iodosuccinamide) can obtain compound (iv). Compound (iv) and commercial reagent (v) are converted into compound (vi) under standard Buchwald conditions or standard Ullmann conditions. Using tin chloride, ferric chloride / activated carbon or palladium carbon hydrogenation reduction of the nitro group to obtain compound (vii). Using a condensing agent such as HATU, HOAT / EDCI, etc. under alkaline conditions, amino compound (vii) and compound (viii) are condensed to obtain a derivative of compound (ix). Compound (ix) is deprotected under acidic conditions to obtain the final product (x).

[0169] Carboxylic acid derivatives ( viii ) can be obtained by the synthesis method described in the literature (see, for example, "Practical synthesis of bicyclicpyrazol-5-one derivatives." Xuejin Feng, Michael A. Xi, Yanjun Wu, Xiaogang Wang, Ning Xi Tetrahedron Lett. 2017, 58, 46-49; Facile synthesis of bicyclic1-arylpyrazol-5-ones." Wu, Y.; Wang, K.; Li, Z.; Bai, X.; Xi, N. Tetrahedron Lett. 2014, 55, 142-147).

[0170] Synthesis Scheme 2:

[0171]

[0172] The compound of formula II of the present invention can be synthesized by Scheme 2. Using a standard amide condensation agent, such as HATU, HOAT / EDCI, etc., under alkaline conditions, the amino compound (vii) and the compound (xi) are condensed to obtain a derivative of the compound (xii). The compound (xii) is deprotected under acidic conditions or palladium carbon hydrogenation conditions to obtain the final product (xiii). Example

[0173] Example 1 (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0174]

[0175] Step 1) 1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0176] Cs2CO3 (1.91 g, 5.85 mmol) was added to a mixture of 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-ol (1.0 g, 3.9 mmol) and 1-fluoro-4-nitrobenzene (550 mg, 3.9 mmol) in DMF (20 mL) at room temperature, and then the mixture was heated to 90°C for 8 h. The mixture was diluted with water (60 mL), and then the mixture was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=2 / 1) to give 1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (845 mg, 51.28% yield) as a white solid. MS(ESI):376.9[M+H] + .

[0177] Step 2) 4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0178] A mixture of 1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (300 mg, 0.80 mmol) in TFA (14 mL) was stirred at 55°C for 3 hours. The mixture was concentrated in vacuo to give 4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (220 mg, 86.17% yield) as a yellow oil, which was used directly in the next step. MS (ESI): 257.1 [M+H] + .

[0179] Step 3) 3-iodo-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0180] At room temperature, KOH (131.37 mg, 2.34 mmol) and I2 (297.17 mg, 1.17 mmol) were added to a solution of 4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (200 mg, 0.78 mmol) in DMF (15 mL), and the mixture was stirred at 70 ° C for 16 hours. LCMS showed that the product was obtained, and then quenched with Na2SO3 aqueous solution (30 mL). The mixture was extracted with EtOAc (20 mL x3), and the combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 3-iodo-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (350 mg, 93.88% yield) as a yellow solid. MS(ESI):383.0[M+H] + .

[0181] Step 4) 3-iodo-1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0182] To a solution of 3-iodo-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (350 mg, 0.92 mmol) in DMF (10 mL) were added K2CO3 (379.22 mg, 2.75 mmol) and PMB-Cl (215.18 mg, 1.37 mmol), and the mixture was stirred at room temperature for 16 h. The mixture was diluted with water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 3-iodo-1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (415 mg, 81.18% yield) as a yellow oil. MS(ESI):502.7[M+H] + .

[0183] Step 5) 4-((3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)aniline

[0184] SnCl2 (224.63 mg, 1.00 mmol) was added to a solution of 3-iodo-1-(4-methoxybenzyl)-4-(4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (100 mg, 0.20 mmol) in EtOH (20 mL), and the mixture was stirred at 65 °C for 2 h. The mixture was concentrated in vacuo and the residue was diluted with H2O (20 mL). The mixture was adjusted to pH 8-9 with aqueous NaHCO3 solution. The mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 4-((3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)aniline (55 mg, 52.64% yield) as a yellow oil. MS (ESI): 472.8 [M+H] + .

[0185] Step 6) (S)-1-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-2-ol

[0186] To a solution of 4-((3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)aniline (50 mg, 0.11 mmol) and (S)-1-aminopropan-2-ol (11.93 mg, 0.16 mmol) in DMSO (5 ml) were added pyrrole-2-carboxylic acid (4.71 mg, 0.042 mmol), K2CO3 (43.84 mg, 0.32 mmol) and CuI (4.03 mg, 0.021 mmol), and the mixture was heated at 70°C for 16 hours. After cooling to room temperature, the mixture was diluted with water (20 mL) and then extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (S)-1-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-2-ol (30 mg, 60.81% yield) as a yellow oil. MS (ESI): 419.9 [M+H] + .

[0187] Step 7) (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0188] To a solution of (S)-1-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-2-ol (25 mg, 0.06 mmol), 2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxylic acid (20.01 mg, 0.08 mmol), HOAt (12.17 mg, 0.09 mmol) and DIEA (38.44 mg, 0.30 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (17.14 mg, 0.09 mmol), and the mixture was heated at 40° C. for 16 h. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×2). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (35 mg, 84.56% yield) as a yellow oil. MS (ESI): 659.8 [M+H] + .

[0189] Step 8) (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0190] A mixed solution of (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (35 mg, 0.05 mmol) in TFA (5 mL) was heated at 60° C. for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (22.3 mg, 0.27 mmol) in H2O (2 mL). The mixture was stirred at room temperature for 2 h. LCMS showed that the product was obtained, and the mixture was filtered and concentrated under reduced pressure to give a crude product, which was purified by preparative HPLC (ACN--H2O (0.1% FA)) to give (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (4.3 mg, 14.88% yield) as a yellow solid. MS (ESI): 539.8 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.10 (s, 1H), 10.70 (s, 1H), 8.12 (d, J = 5.5Hz, 1H), 7.76-7.70 (m, 2H), 7 .62-7.56(m,2H),7.54-7.44(m,3H),7.27-7.22(m,2H),6.01(d,J=5.4Hz,1H),5.33(dd,J=7. 2,4.4Hz,1H),4.81(d,J=4.7Hz,1H),3.91(s,1H),3.57(t,J=5.9Hz,2H),3.21(t,J=6.3Hz,2 H), 3.12-3.05 (m, 1H), 2.04-1.94 (m, 2H), 1.87-1.77 (m, J = 5.6Hz, 2H), 1.11 (d, J = 6.2Hz, 3H).

[0191] Example 2 (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridine-2-yl)-

[0192] 1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0193]

[0194] Step 1) (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0195] To a solution of (S)-1-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-2-ol (25 mg, 0.06 mmol), 2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxylic acid (20.09 mg, 0.08 mmol), HOAt (12.17 mg, 0.09 mmol) and DIEA (38.44 mg, 0.30 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (17.14 mg, 0.09 mmol) at room temperature, and the mixture was heated at 40°C for 16 h. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×2). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (30 mg, 72.32% yield) as a yellow oil. MS (ESI): 660.8[M+H] + .

[0196] Step 2) (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide

[0197] A mixed solution of (S)-N-(4-((3-((2-hydroxypropyl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (30 mg, 0.045 mmol) in TFA (5 mL) was heated at 60° C. for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (22.3 mg, 0.27 mmol) in H2O (2 mL). The mixture was stirred at room temperature for 2 h. LCMS showed that the product was obtained, and the mixture was filtered and concentrated under reduced pressure to give a crude product, which was purified by preparative HPLC (ACN--H2O (0.1% FA)) to give (S)-N-(4-((3-((2-hydroxypropyl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-(pyridin-2-yl)-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxamide (4.7 mg, 19.16% yield) as a yellow solid. MS (ESI): 540.8 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.17(s,1H),10.55(s,1H),8.60(dd,J=4.9,1.1Hz,1H),8.16( s,1H),8.11-8.04(m,1H),7.76(dd,J=8.4,4.9Hz,3H),7.50-7.44(m,1H),7.27(d,J= 8.7Hz,2H),6.03(d,J=5.7Hz,1H),3.92(t,J=5.7Hz,3H),3.73(s,1H),3.34-3.23(m, 3H), 3.17-3.06 (m, 1H), 2.05-1.96 (m, 2H), 1.89-1.80 (m, 2H), 1.11 (d, J = 6.2Hz, 3H).

[0198] Example 3 (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide

[0199]

[0200] Step 1) (R)-2-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol

[0201] To a solution of 4-((3-iodo-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)aniline (71 mg, 0.15 mmol) and (R)-2-aminopropan-1-ol (22.58 mg, 0.30 mmol) in DMSO (5 mL) were added pyrrole-2-carboxylic acid (10.02 mg, 0.09 mmol), K2CO3 (62.22 mg, 0.45 mmol) and CuI (8.59 mg, 0.05 mmol), and the mixture was heated at 70°C for 16 hours. After cooling to room temperature, the mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (R)-2-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol (27 mg, 38.52% yield) as a yellow oil. MS (ESI): 419.9 [M+H] + .

[0202] Step 2) (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide

[0203] To a solution of (R)-2-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol (27 mg, 0.06 mmol), 2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxylic acid (21.79 mg, 0.08 mmol), HOAt (13.15 mg, 0.10 mmol) and DIEA (38.44 mg, 0.30 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (18.52 mg, 0.10 mmol), and the mixture was heated at 40 °C for 16 h. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×2). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (R)-N-(4-((3-((1-hydroxypropyl-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide (43 mg, 95.81% yield) as a yellow oil. MS (ESI): 661.8[M+H] + .

[0204] Step 3) (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide

[0205] A mixed solution of (R)-N-(4-((3-((1-hydroxypropyl-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide (43 mg, 0.07 mmol) in TFA (5 mL) was heated at 60° C. for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (27.3 mg, 0.33 mmol) in H2O (2 mL). The mixture was stirred at room temperature for 2 h. LCMS showed that the product was obtained, and the mixture was filtered and concentrated under reduced pressure to give a crude product, which was purified by preparative HPLC (ACN--H2O (0.1% FA)) to give (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,6,7-tetrahydro-1H-pyrazolo[5,1-c][1,4]oxazine-3-carboxamide (17.1 mg, 48.31% yield) as a yellow solid. MS (ESI): 541.9 [M+H] + . 1 HNMR(400MHz,DMSO)δ12.15(s,1H),10.44(s,1H),8.13(d,J=5.0Hz,1H),7.74(d,J =8.9Hz,2H),7.61(dd,J=10.6,4.6Hz,2H),7.56-7.49(m,3H),7.26(d,J=8.9Hz,2H ),6.00(d,J=5.5Hz,1H),5.12(s,2H),4.10(t,J=5.0Hz,2H),3.77(dd,J=11.9,5.7 Hz, 1H), 3.70 (t, J = 4.9 Hz, 2H), 3.49 (dd, J = 5.2, 2.8 Hz, 3H), 1.20 (d, J = 6.5 Hz, 3H).

[0206] Example 4 (R)-N-(4-((3-((1-hydroxypropyl-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0207]

[0208] Step 1) (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0209] To a solution of (R)-2-((4-(4-aminophenoxy)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)amino)propan-1-ol (40 mg, 0.10 mmol), 2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid (30.29 mg, 0.12 mmol), HOAt (19.48 mg, 0.14 mmol) and DIEA (36.92 mg, 0.30 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (27.43 mg, 0.14 mmol), and the mixture was heated at 40°C for 16 h. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×2). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (R)-N-(4-((3-((1-hydroxypropyl-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide (60 mg, 82.7% yield) as a yellow oil. MS (ESI): 645.8 [M+H] + .

[0210] Step 2) (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0211] A mixed solution of (R)-N-(4-((3-((1-hydroxypropyl-2-yl)amino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide (60 mg, 0.10 mmol) in TFA (5 mL) was heated at 60 ° C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (39.02 mg, 0.46 mmol) in H2O (2 mL). The mixture was stirred at room temperature for 2 hours. LCMS showed that the product was obtained, and the mixture was filtered and concentrated under reduced pressure to give a crude product, which was purified by preparative HPLC (ACN--H2O (0.1% FA)) to give (R)-N-(4-((3-((1-hydroxypropan-2-yl)amino)-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy)phenyl)-2-oxo-1-phenyl-2,4,5,6-tetrahydro-1H-pyrrolo[1,2-b]pyrazole-3-carboxamide (18.9 mg, 38.32% yield) as a yellow solid. MS (ESI): 525.8 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.13(s,1H),10.29(s,1H),8.12(d,J=5.4Hz,1H),7.77(d,J=9 .0Hz,2H),7.54(dt,J=8.6,7.7Hz,4H),7.44-7.39(m,1H),7.26(d,J=8.9Hz,2H),6.0 1(d,J=5.5Hz,1H),5.05(s,1H),4.81(s,1H),3.80(dd,J=14.9,8.1Hz,3H),3.49(qd, J=10.7,5.4Hz,3H),3.17(t,J=7.4Hz,2H),2.47-2.38(m,2H),1.22(t,J=6.6Hz,3H).

[0212] Example 5 N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide

[0213]

[0214] Step 1) 4-(2-Fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine

[0215] At room temperature, Cs2CO3 (1.92 g, 5.9 mmol) was added to a mixture of 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-ol (1.5 g, 5.9 mmol) and 1,2-difluoro-4-nitrobenzene (0.94 g, 5.9 mmol) in DMF (20 mL), and the mixture was heated to 100°C under N2 for 4 hours. The mixture was diluted with water (60 mL), and then the mixture was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (30 mL x4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=2 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (1.7 g, 66.1% yield) as a yellow solid. MS(ESI):394.9[M+H] + .

[0216] Step 2) 4-(2-Fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0217] A mixture of 4-(2-fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (1.7 g, 4.3 mmol) in TFA (15 mL) was stirred at 55 °C for 3 h. The mixture was concentrated in vacuo to give 4-(2-fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (1.1 g, 83.72% yield) as a yellow oil, which was used directly in the next step. MS (ESI): 275.0 [M+H] + .

[0218] Step 3) 4-(2-Fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine

[0219] To a solution of 4-(2-fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (430 mg, 1.57 mmol) in DMF (15 mL) was added KOH (264 mg, 4.71 mmol) and I2 (595 mg, 2.35 mmol) at room temperature, and the mixture was stirred under N2 and 70 ° C for 16 hours. The mixture was quenched with aqueous Na2SO3 solution (30 mL) and then extracted with EtOAc (20 mL x 3). The combined organic layer was washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine (450 mg, 72.0% yield) as a yellow solid. MS(ESI):400.9[M+H] + .

[0220] Step 4) 4-(2-Fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine

[0221] K2CO3 (414 mg, 2.99 mmol) and PMB-Cl (187 mg, 1.19 mmol) were added to a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine (400 mg, 0.99 mmol) in DMF (10 mL), and the mixture was stirred at room temperature for 16 hours. The mixture was diluted with water (30 mL) and then extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (380 mg, 73.1% yield) as a yellow oil. MS(ESI):520.9[M+H] + .

[0222] Step 5) 3-Fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline

[0223] SnCl2 (510 mg, 2.69 mmol) was added to a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (350 mg, 0.67 mmol) in EtOH (20 mL), and the mixture was stirred at 65 ° C for 2 h. The mixture was concentrated in vacuo and the residue was diluted with H2O (20 mL). The pH of the mixture was adjusted to 8-9 with aqueous NaHCO3. The mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM: MeOH = 10 / 1) to give 3-fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline (140 mg, 42.5% yield) as a yellow solid. MS (ESI): 490.6 [M+H] + .

[0224] Step 6) (2S)-1-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-2-ol

[0225] To a solution of 3-fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline (60 mg, 0.12 mmol) and (S)-1-aminopropane-2-ol (18.4 mg, 0.24 mmol) in DMSO (5 mL) were added pyrrole-2-carboxylic acid (8.2 mg, 0.07 mmol), K2CO3 (50.8 mg, 0.37 mmol) and CuI (7.0 mg, 0.037 mmol), and the mixture was heated at 70°C for 16 h. After cooling to room temperature, the mixture was diluted with water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give (2S)-1-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-2-ol (21 mg, 39.3% yield) as a yellow oil. MS (ESI): 438.2 [M+H] + .

[0226] Step 7) N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide

[0227] To a solution of (2S)-1-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-2-ol (20 mg, 0.046 mmol), 2-oxo-1-phenyl-1,2,4,5,6,7-hexahydropyrazolo[1,5-a]pyridine-3-carboxylic acid (20.16 mg, 0.055 mmol), HOAt (9.33 mg, 0.068 mmol) and DIEA (17.7 mg, 0.14 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (13.1 mg, 0.068 mmol), and the mixture was heated at 40° C. for 16 hours. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×3). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=10:1) to give N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide (22 mg, 71.2% yield) as a yellow solid. MS (ESI): 677.9[M+H] + .

[0228] Step 8) N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide

[0229] A mixed solution of N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide (22 mg, 0.033 mmol) in TFA (5 mL) was heated at 60 ° C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (22 mg, 0.27 mmol) in H2O (2 mL). The mixture was stirred at room temperature for 2 hours. The mixture was filtered and concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (ACN--H2O (0.1% FA) gradient: 25 to 50) to give N-{3-fluoro-4-[(3-{[(2S)-2-hydroxypropyl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H,7H-pyrazolo[1,5-a]pyridine-3-carboxamide (4.5 mg, 24.86% yield) as a yellow solid. MS (ESI): 558.2 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.18(s,1H),10.83(s,1H),8.15-8.13(m,1H),7.98(dd,J=13.0,2.3Hz,1H) ,7.62-7.56(m,2H),7.55-7.49(m,1H),7.48-7.45(m,2H),7.42(d,J=8.9Hz,1H),7.37-7.31(m,1 H),6.03(d,J=5.5Hz,1H),3.96-3.89(m,1H),3.58(t,J=6.0Hz,2H),3.29(d,J=4.3Hz,1H),3.20( t,J=6.3Hz,2H),3.14-3.08(m,1H),2.02-1.95(m,2H),1.86-1.79(m,2H),1.11(d,J=6.2Hz,3H).

[0230] Example 6 N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0231]

[0232] Step 1) 4-(2-Fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine

[0233] Cs2CO3 (2.54 g, 7.8 mmol) was added to a mixture of 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-4-ol (2.0 g, 7.8 mmol) and 1,2-difluoro-4-nitrobenzene (1.24 g, 7.8 mmol) in DMF (20 mL) at room temperature, and the mixture was heated to 100°C under N2 for 16 hours. The mixture was diluted with water (60 mL), and then the mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=2 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (2.8 g, 93.3% yield) as a yellow solid. MS (ESI): 394.9 [M+H] + .

[0234] Step 2) 4-(2-Fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine

[0235] A mixture of 4-(2-fluoro-4-nitrophenoxy)-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (2.8 g, 7.1 mmol) in TFA (15 mL) was stirred at 55 °C for 3 h. The mixture was concentrated in vacuo to give 4-(2-fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (1.8 g, 94.7% yield) as a yellow oil, which was used directly in the next step. MS (ESI): 275.0 [M+H] + .

[0236] Step 3) 4-(2-Fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine

[0237] NIS (1.97 g, 8.7 mmol) was added to a solution of 4-(2-fluoro-4-nitrophenoxy)-1H-pyrazolo[3,4-b]pyridine (1.8 g, 6.5 mmol) in CH3CN (15 mL) at room temperature, and the mixture was stirred at 70°C for 16 h. The mixture was quenched with aqueous Na2SO3 solution (30 mL) and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine (1.5 g, 57.7% yield) as a yellow solid. MS (ESI): 400.7 [M+H] + .

[0238] Step 4) 4-(2-Fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine

[0239] K2CO3 (0.61 g, 4.4 mmol) and PMB-Cl (0.69 g, 4.4 mmol) were added to a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1H-pyrazolo[3,4-b]pyridine (1.5 g, 3.7 mmol) in DMF (10 mL), and the mixture was stirred at room temperature for 16 hours. The mixture was diluted with water (30 mL) and then extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (20 mL x 4), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (PE / EtOAc=1 / 1) to give 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (1.56 g, 80.0% yield) as a yellow oil. MS(ESI):520.9[M+H] + .

[0240] Step 5) 3-Fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline

[0241] To a solution of 4-(2-fluoro-4-nitrophenoxy)-3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridine (1.56 g, 3.0 mmol) in EtOH (20 mL) was added SnCl2 (1.14 g, 6.0 mmol) and the mixture was stirred at 65 °C for 2 h. The mixture was concentrated in vacuo and the residue was diluted with H2O (20 mL). The mixture was adjusted to pH 8-9 with aqueous NaHCO3 solution and then extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=10 / 1) to give 3-fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline (0.8 g, 54.4% yield) as a yellow solid. MS (ESI): 490.6 [M+H] + .

[0242] Step 6) 2-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-1-ol

[0243] To a solution of 3-fluoro-4-({3-iodo-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)aniline (0.8 g, 1.6 mmol) and 2-aminopropane-1-ol (0.27 g, 2.4 mmol) in DMSO (10 mL) were added pyrrole-2-carboxylic acid (0.27 g, 2.4 mmol), K2CO3 (0.66 g, 4.8 mmol) and CuI (0.3 g, 1.6 mmol), and the mixture was heated at 70°C for 16 hours. After cooling to room temperature, the mixture was diluted with water (20 mL) and then extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=95 / 5) to give 2-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-1-ol (0.3 g, 71.34% yield) as a yellow oil. MS (ESI): 437.9 [M+H] + .

[0244] Step 7) N-[3-fluoro-4-({3-[(1-hydroxypropan-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0245] To a solution of 2-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-1-ol (150 mg, 0.34 mmol), 2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxylic acid (107.1 mg, 0.41 mmol), HOAT (69.9 mg, 0.51 mmol) and DIEA (132.9 mg, 1.0 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (98.6 mg, 0.51 mmol), and the mixture was heated at 40° C. for 16 hours. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×3). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=10:1) to give N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (160 mg, 68.6% yield) as a yellow solid. MS (ESI): 679.8 [M+H] + .

[0246] Step 8) N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0247] A mixture of N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (160 mg, 0.24 mmol) in TFA (5 mL) was heated at 60 ° C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (100 mg) in H2O (2 mL). The mixture was stirred at room temperature for 2 hours. Filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (ACN--H2O (0.1% FA) gradient: 20 to 40) to give N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-phenyl-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (65.9 mg, 50.3% yield) as a yellow solid. MS (ESI): 559.8 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.23 (s, 1H), 10.56 (s, 1H), 8.15 (d, J = 4.0Hz, 1H), 7.98 ( dd,J=13.0,2.3Hz,1H),7.64-7.58(m,2H),7.56-7.50(m,3H),7.45(t,J=8.8Hz ,1H),7.39(dd,J=8.9,1.9Hz,1H),6.03(d,J=4.0Hz,1H),5.12(s,2H),4.10(t, J=5.0Hz,2H),3.71(t,J=4.9Hz,2H),3.56-3.40(m,2H),1.21(d,J=6.5Hz,3H).

[0248] Example 7 N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0249]

[0250] Step 1) N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0251] To a solution of 2-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-1-ol (150 mg, 0.34 mmol), 2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxylic acid (107.5 mg, 0.41 mmol), HOAT (69.9 mg, 0.51 mmol) and DIEA (132.9 mg, 1.0 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (98.6 mg, 0.51 mmol), and the mixture was heated at 40° C. for 16 hours. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×3). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=10:1) to give N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (150 mg, 64.3% yield) as a yellow solid. MS (ESI): 680.7 [M+H] + .

[0252] Step 2) N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide

[0253] A mixture of N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1-[(4-methoxyphenyl)methyl]pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (150 mg, 0.22 mmol) in TFA (5 mL) was heated at 60 ° C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (100 mg) in H2O (2 mL). The mixture was stirred at room temperature for 2 hours. Filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (ACN--H2O (0.1% FA) gradient: 20 to 40) to give N-[3-fluoro-4-({3-[(1-hydroxypropane-2-yl)amino]-1H-pyrazolo[3,4-b]pyridin-4-yl}oxy)phenyl]-2-oxo-1-(pyridin-2-yl)-4H,6H,7H-pyrazolo[3,2-c]morpholine-3-carboxamide (69.2 mg, 56.2% yield) as a yellow solid. MS (ESI): 560.8 [M+H] + . 1 H NMR (400MHz, DMSO) δ12.21(s,1H),10.38(s,1H),8.62-8.58(m,1H),8.17-8.07(m,2H),8.01-7.95(m,1H),7.84-7.80(m,1H),7.50-7.46(m, 1H),7.45-7.41(m,2H),6.02(d,J=5.5Hz,1H),5.17(s,2H),4.13-4.08(m,4H),3.85-3.77(m,1H),3.54-3.46(m,2H),1.21(d,J=6.5Hz,3H).

[0254] Example 8 N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropane-2-yl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0255]

[0256] Step 1) N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropan-2-yl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0257] To a solution of 2-{[4-(4-amino-2-fluorophenoxy)-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-3-yl]amino}propan-1-ol (90 mg, 0.21 mmol), 2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxylic acid (60.29 mg, 0.25 mmol), HOAT (41.96 mg, 0.31 mmol) and DIEA (79.75 mg, 0.62 mmol) in DCM (20 mL) was added N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (59.15 mg, 0.31 mmol), and the mixture was heated at 40° C. for 16 hours. After cooling to room temperature, the mixture was diluted with DCM (30 mL) and washed with brine (20 mL×3). The separated organic layer was dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash chromatography (DCM / MeOH=10:1) to give N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropane-2-yl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide (80 mg, 58.6% yield) as a yellow solid. MS (ESI): 664.0 [M+H] + .

[0258] Step 2) N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropan-2-yl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide

[0259] A mixture of N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropane-2-yl]amino}-1-(2-methoxy-5-methylphenyl)pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide (80 mg, 0.12 mmol) in TFA (5 mL) was heated at 60 ° C for 2 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the residue dissolved in ACN (7 mL) was added a solution of NaHCO3 (100 mg) in H2O (2 mL). The mixture was stirred at room temperature for 2 hours. Filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC (ACN--H2O (0.1% FA) gradient: 20 to 50) to give N-{3-fluoro-4-[(3-{[(2R)-1-hydroxypropan-2-yl]amino}-1H-pyrazolo[3,4-b]pyridin-4-yl)oxy]phenyl}-2-oxo-1-phenyl-4H,5H,6H-pyrrolo[1,2-b]pyrazole-3-carboxamide (12.0 mg, 18.3% yield) as a yellow solid. MS (ESI): 544.0 [M+H] + . 1 NMR(400MHz,)δ12.15(s,1H),10.36(s,1H),8.10(d,J=4.0Hz,1H),7.99-7 .93(m,1H),7.55-7.46(m,4H),7.43-7.35(m,3H),5.98(dd,J=5.4,0.8Hz, 1H),5.07(d,J=8.0Hz,2H),4.80-4.7(m,1H),3.81-3.70(m,3H),3.50-3.4 4(m,2H),3.14(t,J=7.4Hz,2H),2.44-2.34(m,2H),1.18(d,J=8.0Hz,3H).

[0260] Biological tests

[0261] The LC / MS / MS system used for analysis included an Agilent 1200 series vacuum degassing oven, a binary syringe pump, a well plate autosampler, a column thermostat, and an Agilent G6430 triple quadrupole mass spectrometer with an electrospray ionization (ESI) source. Quantitative analysis was performed in MRM mode, and the parameters for MRM transitions are shown in Table A:

[0262] Table A

[0263] MRA Scanning 490.2→383.1 Fragmentation voltage 230V Capillary voltage 55V Drying gas temperature 350℃ Atomizer 0.276MPa Drying air flow rate 10L / min

[0264] The analysis was performed using an Agilent XDB-C18, 2.1×30 mm, 3.5 μM column, and 5 μL of sample was injected. Analysis conditions: The mobile phase was 0.1% formic acid in water (A) and 0.1% formic acid in methanol (B). The flow rate was 0.4 mL / min. The mobile phase gradient is shown in Table B:

[0265] Table B

[0266] time Gradient of mobile phase B 0.5min 5% 1.0min 95% 2.2min 95% 2.3min 5% 5.0min termination

[0267] In addition, an Agilent 6330 series LC / MS / MS spectrometer equipped with a G1312A binary syringe pump, a G1367A autosampler, and a G1314C UV detector was used for the analysis; the LC / MS / MS spectrometer used an ESI radiation source. Standard solutions were used to perform appropriate cation model processing and MRM transitions for each analyte for optimal analysis. A Capcell MP-C18 column with the specifications of 100×4.6 mm ID, 5 μM (Phenomenex, Torrance, California, USA) was used during the analysis. The mobile phase was 5 mM ammonium acetate, 0.1% methanol in water (A): 5 mM ammonium acetate, 0.1% methanol in acetonitrile (B) (70:30, v / v); the flow rate was 0.6 mL / min; the column temperature was maintained at room temperature; and 20 μL of sample was injected.

[0268] Example A Kinase Activity Assay

[0269] The utility of the compounds disclosed in the present invention as protein kinase inhibitors can be evaluated by the following assay.

[0270] The AXL(h) kinase activity of the compounds of the present invention was tested using the following method:

[0271] The reagents used in the experiment were AXL (Carna Bioscience, Cat No.: 08-107) and FLPeptide30 (PerkinElmer, Cat No.: 760430). The instruments involved were an incubator (ThermoScientific), an oscillator (QILINBEIER), an EZ Reader (PerkinElmer, Cat No.: 122919), a non-contact grade pipetting system (Labcyte Inc., Cat No.: Echo 550), and a non-contact nanoliter pipetting system (TECAN, Cat No.: EVO200).

[0272] Test methods

[0273] Compound dilution: 1) Dissolve the compound in DMSO to an appropriate concentration; 2) Use TECAN EVO200 to perform 3-fold serial dilutions to 10 concentrations in a 384-well microplate, with the highest concentration being 1 mM; Use Echo550 to transfer 20 nL of the solution from the dilution plate to the experimental plate.

[0274] Enzyme assay methods

[0275] 1) Prepare solution 1 as shown in Table C below

[0276] Table C

[0277] Reagent name Solution 1 <![CDATA[MgCl2]]> 10mM Brij-35 0.050% DTT 2mM BSA 0.05% EGTA 1mM HEPE(pH7.5) 50mM AXL 1.333nM

[0278] 2) Add 15uL of solution 1 to each well of the experimental plate and incubate at room temperature for 30 minutes.

[0279] 3) Prepare solution 2 as shown in Table D below:

[0280] Table D

[0281] Reagent name Solution 2 <![CDATA[MgCl2]]> 10mM Brij-35 0.050% DTT 2mM BSA 0.05% EGTA 1mM HEPE(pH7.5) 50mM FLPeptide 6μM ATP 400μM

[0282] 4) Add 5 μL of solution 2 to start the reaction. The final volume of each well is 20 μL. The components in the system are shown in Table E below:

[0283] Table E

[0284] Reagent name Final concentration <![CDATA[MgCl2]]> 10mM Brij-35 0.050% DTT 2mM BSA 0.05% EGTA 1mM HEPE(pH7.5) 50mM FLPeptide 1.5μM ATP 100μM AXL 1nM

[0285] 5) Incubate at 25°C for 90 minutes, then add 75 μL of stop solution (containing 0.5 M EDTA) to terminate the reaction.

[0286] 6) Analyze the samples in each well using the EZ reader.

[0287] Data analysis

[0288] 1) The measured conversion rate (CR) was used to calculate the enzyme's remaining activity (Remaining Activity (%)) according to the following function:

[0289]

[0290] 2) Use XLFit (Equation 201) software to fit and calculate IC 50 .

[0291] The above test method can obtain the IC of inhibition 50 and / or inhibition constant K i IC 50Defined as the concentration of compound that inhibits 50% of enzyme activity under the test conditions. Use 1 / 2log dilution multiples to create a curve containing 10 concentration points and estimate IC 50 Values ​​(e.g., a typical curve is made using the following compound concentrations: 3 μM, 1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM, 0.003 μM, 0.001 μM, 0.0003 μM, 0 μM), or 10 μM, 3 μM, 1 μM, 0.3 μM, 0.1 μM, 0.03 μM, 0.01 μM, 0.003 μM, 0.001 μM, 0 μM).

[0292] For technicians in the field, these are just two of many detection methods, and other methods are also possible.

[0293] Table 1 below provides the AXL(h) kinase test results of the compounds of the present invention, where +: >100 nM; ++: 50-100 nM; +++: <50 nM. The test results show that the compounds of the present invention have a very good inhibitory effect on AXL kinase.

[0294] Table 1. Inhibitory activity of the compounds of the present invention on AXL(h) kinase

[0295]

[0296] Finally, it should be noted that there are other ways to implement the present invention. Accordingly, the embodiments of the present invention are described as examples, but are not limited to the contents described in the present invention, and may also be modified within the scope of the present invention or added to the claims. All publications or patents cited in the present invention will be used as references of the present invention.

Claims

1. A compound having a structure represented by formula (II): or a pharmaceutically acceptable salt; wherein, U1 and U2 are independently N or -C(R a )-; R 1 is phenyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrazolyl, or triazolyl; wherein each of the phenyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, pyrazolyl, and triazolyl groups is independently optionally substituted by 0, 1, 2, 3, or 4 R 11 replace; R a , R 4 , R 5 and R 8 , at each occurrence, independently H, D, F, Cl, Br, -OH, -CN, -NO2, -NH2; R 6 H, D or C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl; R 7 H, D, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl; wherein each C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl, C 3-10 Cycloalkyl, C 3-10 Cycloalkyl C 1-6 Alkyl is optionally substituted with 0, 1, 2, 3, 4, or 5 R 14 replace; R 11 and R 13 , each time it occurs, is independently H, D, F, Cl, Br, -OH, -CN, -NO2, -NH2, C 1-6 Alkyl, C 1-6 Haloalkyl or C 1-6 Hydroxyalkyl; R 14 For H, D, F, Cl, Br, -OH, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1-6 Alkoxy; wherein each C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1-6 The alkoxy groups are optionally substituted by 0, 1, 2, 3 or 4 groups independently selected from H, D, F, Cl, Br, -OH, -NH2, -CN, -NO2, C 1-6 Alkyl and C 1-6 Alkoxy group substitution; n is 0, 1, or 2; X 1 Yes - (CH2) t1 -, or -X 2 -(CH2) t1 -; X 2 is O or S; t1 is 1 or 2; and m is 0, 1, 2, 4, or 5.

2. The compound according to claim 1, wherein R 6 It is H, D, C 1-4 Alkyl, C 1-4 Haloalkyl or C 1-4 hydroxyalkyl; and R 7 H, D, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-4 Alkyl; wherein each C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl, C 3-8 Cycloalkyl, C 3-8 Cycloalkyl C 1-4 The alkyl group is optionally substituted with 0, 1, 2, 3, 4, or 5 R 14 replace.

3. The compound according to claim 1, wherein R 6 Is H or C 1-4 Alkyl; and R 7 It is H, C 1-6 Alkyl, C 1-4 Fluorinated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 Alkyl; wherein R 7 Each C in 1-6 Alkyl, C 1-4 Fluorinated alkyl, C 1-4 Hydroxyalkyl, C 3-6 Cycloalkyl, C 3-6 Cycloalkyl C 1-3 The alkyl group is optionally substituted with 0, 1, 2, 3, 4, or 5 R 14 replace.

4. The compound according to claim 1, wherein R 6 is H, methyl, or ethyl; and R 7 is H, methyl, ethyl, 5. The compound according to claim 1, wherein R a , R 4 , R 5 and R 8 , at each occurrence, is independently H, D, F, Cl or Br.

6. The compound according to claim 1, wherein R 11 and R 13 , independently at each occurrence, is H, D, F, Cl or Br; R 14 For H, D, F, Cl, Br, -OH, C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl or C 1-4 Alkoxy; wherein each C 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Hydroxyalkyl or C 1-4 The alkoxy groups are optionally substituted with 0, 1, 2, 3 or 4 groups independently selected from H, D, F, Cl, Br, -OH, C 1-4 Alkyl and C 1-4 Alkoxy groups are substituted.

7. The compound according to claim 1, which is a compound having one of the following structures: or a pharmaceutically acceptable salt.

8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt according to any one of claims 1 to 7, and a pharmaceutically acceptable excipient, diluent or carrier, or a combination thereof.

9. The pharmaceutical composition according to claim 8, further comprising an additional therapeutic agent.

10. Use of a compound according to any one of claims 1 to 7 or a pharmaceutical composition according to any one of claims 8 to 9 for the preparation of a medicament for preventing, treating, curing, and / or alleviating AXL kinase-mediated diseases, disorders, and / or conditions.

11. The use according to claim 10, wherein the disease and / or condition is selected from a proliferative disease, an autoimmune disease, an allergic disease, an inflammatory disease, transplant rejection, or a viral infectious disease.

12. The use according to claim 10, wherein the disease and / or condition is selected from cancer, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic obstructive pulmonary disease, asthma, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, dermatomyositis, Sjögren's syndrome, psoriasis, type I diabetes, respiratory allergic diseases, sinusitis, eczema, measles, food allergies, insect venom allergies, inflammatory bowel disease, Crohn's disease, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, organ transplant rejection, tissue transplant rejection, cell transplant rejection, influenza, coronavirus infection, dengue virus infection, Zika virus infection, Ebola virus infection, respiratory syncytial virus infection, or HBV.

13. The use according to claim 10, wherein the disease and / or condition is selected from acute myeloid leukemia, acute lymphocytic leukemia or chronic myeloid leukemia.